Material and Methods
This is a retrospective cohort study involving women who presented to our Gynecology Clinic between April 2011 and August 2012. The study protocol was approved by the Institutional Ethic Committee.
Demographic features and medical information regarding menstrual cycles, obstetric and gynecological history, and previous medication and/or disease were collected from the medical records. Body mass index (BMI) was calculated as body weight (in kilograms) divided by height (in meters squared). The waist to hip ratio (W/H) was calculated from dividing the waist circumference by the hip circumference. A total of 1048 consecutive women diagnosed with PCOS were analyzed. PCOS was diagnosed with regard to the Rotterdam criteria, i.e., according to the existence of at least two of the following three features: 1) oligo-or amenorrhea; 2) clinical or biochemical hyperandrogenism; or 3) POM on pelvic ultrasound, after exclusion of other causes of hyperandrogenism, thyroid disorders, hyperprolactinemia, Cushing syndrome, and late onset congenital adrenal hyperplasia. Women with type-1 diabetes mellitus, hepatic or renal pathology, or receiving medication, which could affect carbohydrate metabolism or lipid profile, were also excluded. The follow-chart of subjects is presented in Figure 1 . Oligomenorrhea only (n=167) POM only (n=164) Hirsutism only (n=63) Excluded (n=665); missing history of cycle length (n=86); lack of ultrasonography (103); missing information on hirsutism (n=115); missing data on thyroid and/or prolactin levels (n=361) Excluded (n=830); chronic disease (n=165); congenital uterine and/or ovarian dysplasia (n=27); endometriosis (n=106); hyperprolactinemia (n=88); abnormal thyroid function (n=322); diabetes mellitus type-1 (n=4); premature ovarian failure (n=41); taking medications that may affect the carbonhydrate metabolism, lipid profile or endocrine parameters (n=77)
PCOS subtypes
The participants were divided into two groups: i) those fulfilling the AES criteria (n=504) (15) and ii) women with normoandrogenemic PCOS (oligomernorrhea with POM; n=183). The criteria used to determine the components of the PCOS phenotypes were:
• Clinical hyperandrogenism was determined with a modified Ferriman-Gallewey score>8 (20) .
• Biochemical hyperandrogenism was defined with the existence of at least one of the following findings: serum total testosterone level (tT)>65.82 ng/dL, serum dehydroepiandrosterone sulfate (DHEAS) level>374.9 µg/dL and free androgen index (FAI)>4.94 (calculated on the basis of the 95 th percentile of basal serum androgen normality in the control group of 70 healthy, non-hirsute, eumenorrheic women from the same area (unpublished data).
• Oligomenorrhea was defined as having <8 menstrual cycles/year or menstrual cycles for more than 35 days.
• POM was defined with an antral follicle count (2-9 mm) of≥12 in at least one ovary.
Definition of insulin resistance
Insulin resistance was predicted by using the homeostatic model assessment of insulin resistance (HOMA-IR) (21 
Results

Study population
The medical records of 8906 women were reviewed; 665 women were excluded due to inadequate data, including for unavailable data on the history of the cycle length (n=86), ultrasonographic examination (n=103), hirsutism (n=115), thyroid and/or prolactin laboratory assay (n=361). An additional 830 women were excluded due to the presence of concomitant pathology, including other relevant chronic diseases (n=165), congenital uterine anomalies and/or ovarian dysplasia (n=27), endometriosis (n=106), hyperprolactinemia (n=88), abnormal thyroid function (n=322), diabetes mellitus type-1 (n=4), premature ovarian failure (n=41), and the previous consumption of medications that may affect the carbohydrate pathway, lipid profile, or endocrine parameters (n=77) ( Figure 1 ). The final study population included 687 women diagnosed with PCOS based on Rott-PCOS criteria. While 504 of these women met the AES -PCOS criteria, 183 women were classified as normoandrogenemic PCOS. The prevalence of different PCOS phenotypes is presented in Table 1 .
The prevalence of women with clinical and/or biochemical hyperandrogenism, oligomenorhea (OM), and POM was 7.6, 8.5, and 7.1%, respectively. Demographic characteristics, and the biochemical and anthropometric features of the participants are presented in Table  2 . There were no differences among the PCOS subgroups regarding age (p=0.62; Table 2 ). The mean concentration of C-reactive protein (CRP) in women diagnosed as PCOS according to the AES criteria was significantly higher than that of women classified as normoandrogenemic PCOS (5.96±6.92 vs. 4.21±3.12 mg/L, p=0.003). 
Prevalence of insulin resistance
Prevalence of MetS and dyslipidemia
While the overall rate of metabolic syndrome in women with PCOS was 22.5%, within women diagnosed as PCOS according to the AES-PCOS criteria and normoandrogenemic PCOS, these rates were 25.4 and 10.3%, respectively (p=0.01; Table 3 ). The respective odds ratio for MetS in women with AES-PCOS was 2.95 [95% CI, 1.21-7.21] when compared with subjects classified as normoandrogenemic PCOS. The distribution of the components of metabolic syndrome is also presented in Table 3 .
Regarding the lipid profile, the concentrations of HDLcholesterol, TG, TG/HDL-cholesterol ratio, and VLDL-C were significantly different in women with AES-PCOS from the subjects with normoandrogenemic PCOS (p=0.004, p=0.03, p=0.002, and p=0.02, respectively; Table 2 ). The prevalence of low HDL-cholesterol in the group under the AE-PCOS Society criteria was higher than that of normoandrogenemic PCOS (59.4 vs 41.2%, respectively; p=0.002; Table 3 ), while the prevalence of low HDL-cholesterol was 56.1% in the whole study group. While the prevalence of elevated total cholesterol (≥200 mg/dL) and LDL-C (≥130 mg/dL) parameters in the whole population were 18.3 and 14.6%, respectively, there were no statistically significant differences between women diagnosed as PCOS according to the AE-PCOS Society criteria and women with normoandrogenemic PCOS (18.6% vs. 17.2% and 15.2% vs. 11.6%; p=0.77 and p=0.39, respectively). While the prevalence of elevated TG (≥150 mg/dL) was 21.5% in the whole study group, within the patients diagnosed as PCOS according to the AE-PCOS Society criteria and normoandrogenemic PCOS, these rates were 23.0 and 14.9%, respectively (p=0.09). While the prevalence of elevated TC to HDL-cholesterol ratio (≥5.6) in the whole population was 7.6% within women diagnosed as PCOS according to AE-PCOS, this rate did not differ from subjects with normoandrogenemic PCOS (8.5 and 3.5%, respectively; p=0.12).
Discussion
In the current study, the prevalence of PCOS according to the Rotterdam and AE-PCOS Society criteria in a Caucasian population were 9.3 and 6.8%, respectively. Although the results of the current study are in concurrence with the previously reported frequency's ranging from 11.2 to 20.9% according to the Rotterdam criteria (18, 26-28), we found lower figures than a prior Turkish cohort study using the AE-PCOS Society criteria (18) . Further, data from this study illustrated that the prevalence of insulin resistance and impaired glucose tolerance barely rise in the overall PCOS population (31.7 and 17.8%, respectively) when compared to that reported from another study of Turkish women with PCOS (29) . This study has also shown that women with PCOS have a higher prevalence of metabolic syndrome (22.5%) than that consistently reported from the literature, albeit with a varying rate (17, 18, 28) . Although there is limited data on the association of the new phenotype (normoandrogenemic PCOS) and its implications on the metabolic profile, it has been reported that the normoandrogenemic PCOS phenotype has a milder metabolic syndrome with a rather similar rate of insulin resistance (30) . The evidence currently suggests that patients with PCOS diagnosed according to AE-PCOS Society criteria have the most severe metabolic features (15, 17) . Women in PCOS without hyperandrogenism are still the subject of debate (2, 15, 16) . The Androgen Excess and PCOS Society suggested that PCOS initially should be accepted as a condition of hyperandrogenism (15) . The current study demonstrated that in women diagnosed according to AE-PCOS Society criteria, the proportion of increased serum glucose level was double in comparison with that in women identified as normoandrogenemic PCOS, while the rate of women with an abnormal glucose tolerance test and insulin resistance rose by almost 10%. These findings appear to support the previous observations that women with normoandrogenemic PCOS exhibit a small proportion of hyperglycemia and insulin resistance (31, 32 ). An impaired lipid profile is a prevalent finding in women with PCOS (33, 34) , and also it was recently noted that the TG, LDL-cholesterol, and TC levels are significantly higher in obese PCOS women than in lean/normo-weight PCOS women, irrespective of the PCOS phenotypes (35) . Women with hyperanderogenemic PCOS showed the most atherogenic lipid profiles, with higher apolipoprotein B compared to the other PCOS phenotypes (36) . However, conflicting data are present in the literature. Moreover, despite the similar rate of IR in BMI-matched PCOS phenotypes, free testosterone and FAI were positively correlated with triglyceride as well as being inversely correlated with HDL-cholesterol (37) . Conversely, other researchers speculate that lipid abnormalities are not different in women with hyperandrogenemic PCOS (38, 39) . In accordance with the previous study, we also observed that women with normoandrogenemic PCOS have a lower triglyceride/HDL-cholesterol ratio, triglyceride, and VLDL-cholesterol concentrations as well as higher HDL-cholesterol levels when compared with those of women diagnosed as PCOS according to the AES-PCOS criteria, although BMI was not significantly different between the PCOS phenotypes (37) . These findings suggest that hyperandrogenemia may adversely affect the lipid metabolism regardless of the presence of MetS or IR. However, the higher prevalence of decreased HDL-cholesterol with a similar rate of elevated TG, total cholesterol, and LDL-cholesterol observed in this study may indicate the effects of insulin resistance on HDLcholesterol. Further, this finding would be an indirect reflection of increased ovarian androgen secretion in women with PCOS, as proposed in previous reports (40, 41) .
According to the new diagnostic criteria (2, 13), PCOS may de facto involve a large-scale number of abnormalities, consisting of women with mild clinical and hormonal abnormalities (42, 43) . As regards metabolic syndrome (evaluated with the International Diabetes Federation criteria), our cohort study showed a proportion of 22.1% had it in the overall PCOS population according to the Rotterdam criteria consistent with a previous cohort study in a Mediterranean population (44) . Furthermore, women diagnosed with PCOS according to the AE-PCOS Society criteria had a higher rate of MetS than those with normoandrogenemic PCOS (20.4 vs 9.2%). This significant difference is in line with previous studies (45) (46) (47) (48) . The explanation for this quite pronounced difference may be that the key features of MetS comprising abdominal obesity, insulin resistance, and impaired glucose tolerance are present less frequently in normoandrogenemic PCOS (24) . Indeed, a current meta-analysis showed that elevated serum androgen levels have a positive correlation with the prevalence of MetS (49) . Overall, women with normal androgen levels appear to be part of the milder PCOS spectrum, but this might be due to the less frequently elevated blood glucose level, which is related with lower health-risk-related factors. It has also been found that subclinical atherosclerosis expressed as low-grade inflammation (increased hs-CRP levels) could be a factor for an increased risk of cardiovascular disease and DM type 2 in women with PCOS (50) (51) (52) . Moreover, an elevation in circulating hs-CRP irrespective of obesity is evidence that chronic low-grade inflammation may have an effect on the pathogenesis of PCOS, particularly in hyperanderogenemic phenotypes (4, 53) . In accordance with previous reports, we also observed a significant elevation of hs-CRP in women with hyperanderogenemia compared to in women with normal androgen levels, despite there being no difference in BMI between the phenotypes (4, 53) . This assumes that a high androgen level independently may be a factor that affects the establishment of cardiovascular disease in women diagnosed as PCOS. Limitations for the study include that the methodology of study was a retrospective cohort, and also the numbers in the normoandrogenemic PCOS group were too small to assess the statistical significance for the oral glucose test intolerance. In conclusion, women with hyperandrogenemic PCOS usually present an impaired lipid profile, insulin resistance, and abnormal glucose tolerance, which may be related to the subsequent development of MetS. PCOS patients with androgen excess appear to be exposed to a higher risk of cardiovascular disease than normoanderogenemic PCOS patients (54, 55) . The observations of the present study suggest that the androgen excess per se is related with a long-term-health-risk of PCOS. This new data may be of reference in informing women diagnosed as PCOS, even though further prospective studies are needed to validate this proposition.
